Overview

Price chart · mood · technical indicators

RNAZ

Transcode Therapeutics Incstock Healthcare

Biotechnology

$7.7423.66%Current Market Mood:Strong Bearish

Market Mood

Price Range (1Y)

$6.08$20.99

Current: $7.74

Market Comparison

vs Healthcare Sector & Biotechnology Industry

RNAZ

-23.66%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio—

EPS (TTM)$-52.590.0% YoY

Profit margin0.0%HEALTHCARE

Market cap$7.2MMicro cap

Valuation

Forward P/E: —
PEG ratio: —
P/B: 0.71
P/S (TTM): —
EV/EBITDA: -0.59

Profitability & growth

ROE (TTM): -46.3%
Operating margin: 0.0%
Revenue growth YoY: 0.0%
Dividend yield: —
Beta: 1.40

Last earnings

Feb 25, 2026 · Reported $-16.42

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Transcode Therapeutics Inc

Company profile

TransCode Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development and commercialization of drugs for the treatment of metastatic diseases. The company is headquartered in Boston, Massachusetts.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 6 LIBERTY SQUARE, BOSTON, MA
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$7.2M

Shares outstanding$916970

52W high$20.99

52W low$6.08

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

RNAZ

Market Comparison

Fundamentals

Valuation

Profitability & growth

News & Sentiment

TransCode Therapeutics (NASDAQ: RNAZ) registers 15.96M resale shares by selling holders

TransCode Therapeutics (NASDAQ: RNAZ) updates 2025 governance, executive pay and ownership

TransCode names Anna Moore scientific board chair

Transcode Therapeutics appoints Dr. Anna Moore as chair of scientific advisory board

TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University

TransCode Therapeutics signs financing deal worth up to $20 million

YA II affiliates report 101,772 shares in TransCode Therapeutics (RNAZ) under convertible note

TransCode Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025

TransCode Therapeutics Secures New Financing to Extend Runway

TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028

TransCode Therapeutics Secures $20M Financing

TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028

TransCode Therapeutics Secures Up to $20 Million Flexible Financing to Advance Lead Cancer Program and Extend Runway Into 2028

TransCode Therapeutics Secures New Financing to Extend Runway

Transcode Therapeutics Secures Up To $14 Million Standby Equity Facility and $6 Million Notes With Yorkville

TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028

TransCode Therapeutics (NASDAQ: RNAZ) lines up up to $20M in new flexible funding

TransCode lands $20M to keep its cancer trial funded into 2027

Responsive Playbooks and the RNAZ Inflection

RNAZ PE Ratio & Valuation, Is RNAZ Overvalued

About Transcode Therapeutics Inc

Classification

Company profile

RNAZ

Market Comparison

RNAZ Market Analysis

Overview

RNAZ

Market Comparison

Fundamentals

Valuation

Profitability & growth

News & Sentiment

TransCode Therapeutics (NASDAQ: RNAZ) registers 15.96M resale shares by selling holders

TransCode Therapeutics (NASDAQ: RNAZ) updates 2025 governance, executive pay and ownership

TransCode names Anna Moore scientific board chair

Transcode Therapeutics appoints Dr. Anna Moore as chair of scientific advisory board

TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University

TransCode Therapeutics signs financing deal worth up to $20 million

YA II affiliates report 101,772 shares in TransCode Therapeutics (RNAZ) under convertible note

TransCode Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025

TransCode Therapeutics Secures New Financing to Extend Runway

TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028

TransCode Therapeutics Secures $20M Financing

TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028

TransCode Therapeutics Secures Up to $20 Million Flexible Financing to Advance Lead Cancer Program and Extend Runway Into 2028

TransCode Therapeutics Secures New Financing to Extend Runway

Transcode Therapeutics Secures Up To $14 Million Standby Equity Facility and $6 Million Notes With Yorkville

TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028

TransCode Therapeutics (NASDAQ: RNAZ) lines up up to $20M in new flexible funding

TransCode lands $20M to keep its cancer trial funded into 2027

Responsive Playbooks and the RNAZ Inflection

RNAZ PE Ratio & Valuation, Is RNAZ Overvalued

About Transcode Therapeutics Inc

Classification

Company profile

RNAZ

Market Comparison